4 February 2025
RUA Life
Sciences Plc
("RUA Life Sciences",
the "Company" or the
"Group")
Director/PDMR
Shareholding
RUA Life Sciences (AIM: RUA), the
holding company of a group of medical device businesses focused on
the exploitation of the world's leading long-term implantable
biostable polymer (Elast-Eon™), announces that it has been notified
that Bill Brown, Chief Executive Officer of the Company, on 3
February 2025, purchased 65,000 ordinary shares in the Company at a
weighted average price of 13.30 pence per ordinary
share.
Following this purchase, Bill Brown
is interested in 906,876 ordinary shares in the Company,
representing approximately 1.46 per cent. of the Company's issued
ordinary share capital.
The
Company makes the following disclosures in accordance with article
19(3) of the Market Abuse Regulation:
|
1
|
Details of the person discharging
managerial responsibilities / person closely associated
|
|
a)
|
Name
|
Bill Brown
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial
|
|
3
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name
|
RUA Life Sciences plc
|
|
b)
|
LEI
|
213800BMVB22PVOJ9Z28
|
|
4
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
|
Transaction
|
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 5 pence
each
ISIN: GB0033360586
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
13.39 pence
13.16 pence
|
40,000
25,000
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
65,000
£8,644.98
|
|
e)
|
Date of the transaction
|
3 February 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
|
- Ends -
For
further information contact:
|
RUA
Life Sciences
Bill Brown, CEO
Lachlan Smith, CFO
|
Tel: +44 (0)1294 317073
Tel: +44 (0)1294 317073
|
|
Cavendish Capital Markets
Limited
(Nominated Adviser and Broker)
Giles Balleny/Dan
Hodkinson (Corporate Finance)
Charlie
Combe (Broking)
Michael
Johnson (Sales)
|
Tel: +44 (0)20 7220 0500
|
About RUA Life Sciences
The RUA Life
Sciences group was created in April
2020 when RUA Life Sciences Plc (formerly known
as AorTech International Plc) acquired RUA Medical
Devices Limited to create a fully formed medical device
business. RUA Life Sciences is the holding company of the
Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives
of millions of patients by enabling medical devices with
Elast-EonTM, the world's leading long-term implantable polyurethane.
Whether it is licensing Elast-EonTM, manufacturing a device or
component, or developing next generation medical devices,
a RUA Life Sciences business is pursuing our
vision.
Elast-Eon™'s biostability is
comparable to silicone while exhibiting excellent mechanical, blood
contacting and flex-fatigue properties. These polymers can be
processed using conventional thermoplastic extrusion and moulding
techniques. With over 8 million implants and 15 years of successful
clinical use, RUA's polymers are proven in long-term life enabling
applications.
The Group's four business units
are:
|
RUA
Contract Manufacture:
|
End-to-end contract developer and
manufacturer of medical devices and implantable fabric
specialist.
|
|
RUA
Biomaterials:
|
Licensor of
Elast-EonTM polymers to the medical device industry.
|
|
RUA
Vascular:
|
Commercialisation of open surgical
vascular grafts and patches
|
|
RUA
Structural Heart:
|
Development of polymeric leaflet
systems for heart valves.
|
